---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-280112"
form_type: "8-K"
ticker: "TNYA"
cik: "0001858848"
company_name: "Tenaya Therapeutics, Inc."
filed_at: "2024-12-17T23:59:59+00:00"
generated_at: "2026-05-29T02:34:23.843694+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Tenaya's TN-201 shows robust cardiac transduction, increasing mRNA and protein in 3 HCM patients

## Summary
- TN-201 well tolerated at 3E13 vg/kg; no cardiac toxicities or TMA; liver enzyme elevations managed with corticosteroids.
- Robust cardiac transduction at Week 8 above preclinical efficacy levels; TN-201 mRNA increased 50% at Week 52 in Patient 1.
- MyBP-C protein level increased 3% from Week 8 to 52 in Patient 1; baseline biopsies added for future quantification.
- Clinical measures mostly stable/improved: NT-proBNP stable, troponin I normalized in Patient 2; NYHA class improved.
- Further data from Cohort 1 and higher-dose Cohort 2 expected in 2025.

## SEC filing metadata
- accession: 0001193125-24-280112
- form_type: 8-K
- ticker: TNYA
- cik: 0001858848
- company_name: Tenaya Therapeutics, Inc.
- filed_at: 2024-12-17T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1858848/000119312524280112/0001193125-24-280112-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1858848/000119312524280112/d883027d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-280112
- JSON: https://secwatch.observer/filing/0001193125-24-280112.json
- Plain text: https://secwatch.observer/filing/0001193125-24-280112.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.